Näiden koulutusten sisältö on Novo Nordiskista riippumattoman sisällöntuottajan tuottamaa. Osa koulutuksista on EACCME-akkreditoituja, joten niitä voidaan lukea hyväksi joidenkin erikoisalojen erikoistumisopinnoissa ja diabeteksen erityispätevyyttä suoritettaessa. Pisteiden kelpoisuus täytyy kuitenkin varmistaa kolutuksesta vastaavalta taholta. Novo Nordisk ei vastaa koulutusten sisällöstä. Osa koulutusten järjestäjistä vaatii luomaan erilliset tunnukset omalle sivustolleen.
This course is developed by Medscape Education Global. Medscape is one of the leading digital platforms for medical education. A comprehensive array of innovative formats, in multiple languages, insures the right educational solution is available to best achieve desired objectives—from text-based articles to state-of-the-art multimedia formats and the most sophisticated simulation environments. Activity formats include Clinical Insights, Expert Perspective, Instructional Series Programming, Next-Generation Symposia, Patient-Case Approaches, including Simulation and Clinical Advances.
In this diabetes expert encounter, Drs Michael Nauck from Bochum, Germany, and Xavier Cos from Barcelona, Spain, discuss the rationale and the specifics of the latest guideline recommendations for the appropriate use of long-acting and next-generation GLP-1 receptor agonists in patients with type 2 diabetes. A particular focus is on implementing their targeted usage in clinical practice and practical aspects of intiating and titratingthese incretin-based therapies safely and effectively in a primary care setting.
An overview of currently available GLP-1 RA injectable formulations is included, and reference is made to the so far only available oral formulation of a long-acting GLP-1 RA.
Made for: Diabetologists, Endocrinologists, Cardiologists, Primary Care Physicians
Disease areas: Diabetes
Developed by: Medscape
